Jae Choe
Family Medicine · Los Angeles, CANPI 1144849910
Payments from drug & device makers
Across 88 payments — averaging $35.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$503
- Amgen$371
- IBSA Pharma Inc.$310
- Bayer$260
- AstraZeneca$217
- AbbVie$217
- plus $1K from 15 others
What the payments were for
- Food & beverage$3,165100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 6 | $503 |
| Amgen | 19 | $371 |
| IBSA Pharma Inc. | 5 | $310 |
| Bayer | 6 | $260 |
| AstraZeneca | 5 | $217 |
| AbbVie | 6 | $217 |
| Ironwood Pharmaceuticals, Inc | 3 | $174 |
| Boston Scientific | 1 | $158 |
| GSK | 7 | $155 |
| Novo Nordisk | 7 | $151 |
| Phathom Pharmaceuticals, Inc. | 1 | $150 |
| Exact Sciences | 5 | $99 |
| Ardelyx, Inc. | 3 | $91 |
| Novartis | 4 | $83 |
| Boehringer Ingelheim | 3 | $65 |
| Merck | 2 | $40 |
| Lilly USA, LLC | 1 | $31 |
| Sanofi Pasteur Inc. | 1 | $28 |
| Pfizer | 1 | $23 |
| Agios Pharmaceuticals, Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,165 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 25 | $22,781 |
| OzempicSemaglutide | 13 | $14,587 |
| KerendiaFinerenone | 11 | $6,412 |
| Diclofenac Sodium | 26 | $1,799 |
| Levothyroxine Sodium | 32 | $970 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 31 | $970 |
| Atorvastatin Calcium | 109 | $669 |
| Tamsulosin Hcl | 27 | $381 |
| Telmisartan | 17 | $366 |
| Rosuvastatin Calcium | 29 | $335 |
| Metformin Hcl | 38 | $294 |
| Celecoxib | 11 | $260 |
| Amlodipine Besylate | 53 | $196 |
| Mirtazapine | 13 | $173 |
| Fluticasone Propionate | 12 | $162 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $65 | $22,78125 claims |
| Novo NordiskOzempic | $151 | $14,58713 claims |
| BayerKerendia | $260 | $6,41211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.
Other family medicine in Los Angeles
- Albert NassirLos Angeles$5.7M
- Nader SobhLos Angeles$4.1M
- Alexander RivkinLos Angeles$2.8M
- Pamela KushnerLos Angeles$1.2M
- Scott HowellLos Angeles$793K
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.